Santo Therapeutics Raises Multi-Million (GBP-Equivalent) Round Led by FIRHealth Capital

• Investment will accelerate development of Santo’s in vivo lentiviral gene therapy pipeline
• Funding supports dual IND filings in China and the United States
• Round led exclusively by FIRHealth Capital

Hangzhou, China, 9 October 2025:  Santo Therapeutics, a pioneering biotech company developing next-generation lentiviral gene therapies, has completed an Angel+ financing round raising multi-million (GBP-equivalent) Angel+ round, led exclusively by FIRHealth Capital.

The new investment will accelerate the development of Santo’s in vivo lentiviral gene therapy pipeline, advance its CMC and preclinical programmes, and support dual IND filings in China and the United States.

A spokesperson for Santo Therapeutics said:

“The FIRHealth team brings deep scientific insight and long-term commitment to biotechnology innovation, giving us strong confidence in our partnership. This investment recognises Santo’s leadership in lentiviral vector design and reflects our shared vision to drive global progress in gene therapy.”

FIRHealth Capital commented:

“We continue to focus on transformative opportunities in cell and gene therapy. Santo’s expertise in lentiviral vector engineering and its global development strategy have impressed us. We are excited to support the team as they advance their platform toward clinical and commercial milestones.”

About Santo Therapeutics

Founded in Hangzhou, Santo Therapeutics is developing a differentiated platform that combines AI-driven vector design, in vivo CAR-T innovation and proprietary lentiviral manufacturing capabilities. Santo Therapeutics is one of the occupiers at Stevenage Bioscience Catalyst (SBC), a leading UK hub for early-stage therapeutics and cell and gene therapy. The company maintains an office base on the campus, connecting its global team with the wider SBC community of innovative life-science companies Its lead programmes target oncology and rare genetic diseases and are advancing toward first-in-human clinical trials.

–Ends–

Contact
Doreen Li, CFO
Santo Therapeutics Co., Ltd. Email: doreen@santobiopharma.com
Mobile: +44 7422 905757